Drug Trial Radar · NCT03552263
Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)
Last checked: Nov 19, 2026Latest source record: Nov 13, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
132
Actual
Start
Jun 7, 2018
Primary completion
Oct 20, 2019
Study completion Nov 10, 2019
Sponsor
- Lead sponsor
- Tasly Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 11, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Acute mountain sickness (AMS) is one of three syndromes of altitude illness. It is very common when people venture over 2500 meters altitude. This illness is mainly induced by acute exposure to low partial pressure of oxygen at high altitude that will cause a pathological effect on humans. T89 capsule is a modernized industrialized traditional Chinese herbal medicine. It is a botanical drug for oral use. In recent years, several literatures and clinical studies have showed that oral administration of T89 may provide substantial benefits in the prevention or alleviation of symptoms associated with acute mountain sickness (AMS), including nausea, vomiting, headache, dizziness, fatigue, and sleep disturbance. Such effect was also observed in a pilot clinical study recently conducted in Tibet in China. This study is a prospective, double-blind, randomized, placebo-controlled phase 2 clinical trial having three arms including T89 low-dose, T89 high-dose and a placebo controlled group. People will be screened against the inclusion/exclusion criteria after informed consent signed. Eligible subjects will be randomly assigned into one of three arms and instructed to use T89 orally twice daily for 14 days (Days 1-14) before ascending, and 5 days after ascending during the observation period (Days 15-19). The primary efficacy parameter is Lake Louise Scoring System (LLSS) which will be evaluated by subject-self and principal investigator in clinic.
Conditions
- Acute Mountain Sickness (AMS)
Interventions
T89 capsuleDrug
T89 capsules (75mg), orally, twice daily.
Placebo capsuleDrug
Placebo capsules (0mg), orally, twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The LLSS self- and clinical assessments score on Day 16 morning(next morning of arrival at high altitude) between T89 and Placebo groups.Time frame: Day 16 morning (next morning of arrival at high altitude)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hypoxia Research Lab, UCSF Parnassus Campus, S-256
San Francisco, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.